BioMed Central
British academic publisher
BioMed Central (BMC) is a United Kingdom-based, for-profit scientific open access publisher that produces over 250 scientific journals. All its journals are published online only. BioMed Central describes itself as the first and largest open access science publisher. It was founded in 2000 and has been owned by Springer, now Springer Nature, since 2008.
History
BioMed Central was founded in 2000 as part of the Current Science Group (now Science Navigation Group, SNG), a nursery of scientific publishing companies. SNG chairman Vitek Tracz developed the concept for the company after NIH director Harold Varmus's PubMed Central concept for open-access publishing was scaled back. The first director of the company was Jan Velterop. Chemistry Central was established in 2006 and the PhysMath Central journal imprint in 2007.
In 2002, the company introduced article processing charges, and these have since been the primary source of revenue. In 2007, Yale University Libraries stopped subsidizing BioMed Central article processing charges for Yale researchers.
Begin with the source’s own compact description: “BioMed Central” is british academic publisher. The dossier treats that line as a proposition to test through BioMed, Central and British, not as a finished interpretation.
Why this record matters
The phrase “british academic publisher” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Apr 21, 2026. The linked authority identifier is Q463494. VIAF identifies the subject as 153945870. The Library of Congress control number is no2002099791. 2 of 4 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 2000, 2008, 2006 and 2007.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “BioMed Central”, its source revision and the description used here.
- Expand the search: follow BioMed Central primary sources, BioMed Central archive and BioMed research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “BioMed Central”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “BioMed Central” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.